Letteratura Scientifica

Ageing is a scientifically fascinating and complex biological occurrence characterised by morphological and functional changes due to accumulated molecular and cellular damage impairing tissue and organ function. Ageing is often accompanied by cognitive decline but is also the biggest known risk factor for Alzheimer’s disease, the most common form of dementia.

The uniform lifestyles of participants minimized potential confounds of the study.
∙ Early-life cognitive ability influenced late-life cognitive outcomes.
∙ Some participants with AD pathology did not exhibit dementia.
∙ Neuropathological comorbidities were common and increased the risk of dementia.

Seasons change, fashions change, US presidents change, but for many patients, prescriptions never do—except to become more numerous...

Deprescribing is the intentional dose reduction or discontinuation of a medication. The development of deprescribing interventions should take into consideration important organizational, interprofessional, and patient-specific barriers that can be further complicated by the presence of multiple prescribers involved in a patient's care. Patients who receive care from an increasing number of prescribers may experience disruptions in the timely transfer of relevant healthcare information, increasing the risk of exposure to drug–drug interactions and other medication-related problems...

Literature regarding anticoagulants in older people affected by atrial fibrillation (AF) is limited to retrospective studies, poorly considering the importance of multidimensional frailty. The main objective of this study is to evaluate in hospitalised older persons with AF the benefit/risk ratio of the anticoagulant treatments, considering the severity of frailty, determined by the multidimensional prognostic index (MPI).

Nursing home residents are at high risk for infection, hospitalization, and colonization with multidrug-resistant organisms.

Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer’s disease. Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer’s disease.

Konstantinos Prokopidis 1, Masoud Isanejad 1, Asangaedem Akpan 1 2, Maria Stefil 3 4, Behnam Tajik 5 6, Panagiotis Giannos 7, Massimo Venturelli 4, Rajiv Sankaranarayanan 3 8